The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLC
Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses second interim overall survival findings from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab with chemotherapy (carboplatin/pemetrexed) in patients with EGFR-mutant, advanced non-small cell lung cancer (NSCLC) following progression on osimertinib. At the second interim analysis, overall survival (OS) improved, but did not meet the significance threshold. Amivantamab with chemotherapy also significantly prolonged post-progression outcomes, including progression-free survival 2 (PFS2), time to treatment discontinuation, and time to subsequent therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
